Developer docs
API playgroundTry for free, no card

Search company profiles

Cureverse

Full company profile

uuid0002lok

Namestring
Cureverse
Legal namestring
주식회사 큐어버스 (Jushikhoesa Cureverse)
Websiteurl
cureverse.co.kr
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Cureverse (큐어버스) is a Seoul, South Korea-based clinical-stage biotech founded in October 2021 as a technology spin-off from the Korea Institute of Science and Technology (KIST), operating with approximately 10 employees. The company develops orally bioavailable, brain-penetrant small molecule drugs for intractable central nervous system diseases and oncology, organized around a proprietary 'Right Structure' / 'ALL-R-IGHT Structure' medicinal chemistry design philosophy. Its discovery platform integrates scaffold hopping, Fragment-Based Drug Discovery (FBDD), Differential Scanning Fluorimetry (DSF), and a proprietary in-house 'li-structure' (likelihood-to-be-a-drug) compound library customized per disease target to engineer drug-like properties (BBB permeability, ADMET, formulation ease) into candidates from the initial design stage.

The pipeline consists of five distinct small molecule candidates targeting different diseases and stages: CV-01, an oral selective Keap1/Nrf2 activator (first-in-class) for Alzheimer's and other neurodegenerative diseases, currently in Korean Phase 1 with a European bridge CTA planned for April 2026; CV-02, a biased S1P1 receptor agonist (best-in-class) for multiple sclerosis with US FDA Phase 1 IND approval received June 2025; CV-03, a selective DDR1 inhibitor for KRAS G12X-mutant lung and pancreatic cancers (preclinical, KDDF-selected); CV-P, a next-generation PPARδ agonist for metabolic/inflammatory diseases; and CV-T, a Tau aggregation inhibitor for Alzheimer's and related tauopathies.

Cureverse's business model is licensing- and partnership-driven rather than direct commercialization. The landmark October 2024 USD 370M technology transfer to Italy's Angelini Pharma for CV-01 global rights (ex-Korea/China) generated the bulk of 2025 recognized revenue (cumulative >KRW 10B / ~$7M), with the company pursuing a repeatable tech-transfer strategy targeting two additional preclinical/Phase 1 deals within five years. The company supplements licensing income with non-dilutive Korean government R&D grants (KDDF, DIPS, Global Cluster R&BD, KIST Biostar), Series B and planned pre-IPO venture funding (cumulative ~KRW 34B raised), and is targeting a 2027 KOSDAQ technology-special listing with Mirae Asset Securities as lead underwriter. Direct or partnered self-commercialization in Korea and China is planned post-Phase 3, with active partner search underway.

Short descriptiontext

Cureverse is a Seoul-based, KIST spin-off clinical-stage biotech (founded 2021, ~10 employees) developing orally bioavailable, brain-penetrant small molecule drugs for CNS diseases and oncology across five pipeline assets, monetized primarily through global out-licensing deals and government R&D grants ahead of a 2027 KOSDAQ IPO.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
small molecule drug discovery, CNS therapeutics development, oncology drug pipeline, pharmaceutical licensing deals, biotech pipeline assets
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Drug Discovery and Development
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Licensing & Royalty Income (CV-01)
TypeLicensing Royalties
Description

Out-licensing of CV-01 to Angelini Pharma for global rights ex-Korea/China, structured as an upfront payment plus development/regulatory/sales milestone payments (total contract value USD 370M / ~KRW 500–537B) plus ongoing sales royalties. Korea and China commercial rights retained by Cureverse for self-development.

cureverse.co.kr
2Tech Transfer / Out-licensing Pipeline
TypeLicensing Royalties
Description

Strategy of repeatedly executing early-stage (preclinical or Phase 1) tech transfer deals for each pipeline asset to generate milestone-based cash flow that funds further internal pipeline development. CEO targets two additional tech transfer deals within five years.

cureverse.co.kr
3Government R&D Grants (National/Regional Programs)
TypeLicensing Royalties
Description

Non-dilutive R&D funding from Korean government programs including KDDF (Korea Drug Development Fund), Korea National R&D Program for Dementia, DIPS (Deep Tech TIPS 1000+), Korea SMEs & Startups Agency (아기 유니콘), Seoul R&D, KIST biostar, and Global Cluster R&BD. Funds preclinical, IND, and clinical bridging studies.

cureverse.co.kr
4Venture Capital Investment (Series B and Pre-IPO)
TypeLicensing Royalties
Description

Venture capital funding, including a KRW 25B Series B closed in early 2025 (cumulative KRW 34B raised), with a planned pre-IPO round in H2 of the IPO year to support Phase 2/3 development and commercialization infrastructure.

cureverse.co.kr
5Future Direct Self-Commercialization (Korea/China rights)
TypeLicensing Royalties
Description

Planned direct sale of CV-01 (and potentially other assets) in Korea and China markets where Cureverse retains commercial rights, with active partner search for a single licensee for both territories. Currently searching for a Korean partner with a China network.

cureverse.co.kr
Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Bespoke licensing deal pricing (CV-01 to Angelini Pharma)
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is bespoke and not publicly disclosed as a catalog. The publicly reported CV-01 deal to Angelini Pharma was USD 370M (~KRW 500B–537B) comprising an undisclosed upfront plus development/regulatory/sales milestones, with separate sales royalties. Cureverse retains Korea/China commercial rights and is seeking a single partner for these markets. Bespoke B2B licensing; pricing is per-asset, negotiated with each partner.

cureverse.co.kr
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cureverse is a preclinical-to-clinical-stage Korean biotechnology company that discovers and develops first-in-class and best-in-class small molecule drug candidates for intractable CNS, oncology and inflammatory/fibrotic diseases using a proprietary structure-based medicinal chemistry platform ('Right Structure' / 'ALL-R-IGHT structure'). Its current commercial offerings are pipeline drug assets — CV-01 (oral Keap1/Nrf2 activator), CV-02 (biased S1P1 agonist), CV-03 (DDR1 inhibitor), CV-P (next-generation PPARδ agonist) and CV-T (Tau aggregation inhibitor) — which it monetizes primarily through B2B out-licensing, co-development and technology transfer deals with global pharmaceutical partners (anchor transaction: USD 370M CV-01 deal with Angelini Pharma in October 2024).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cureverse is a single-platform Korean biotech company built around a proprietary small-molecule drug discovery engine called 'Right Structure' (operationalized as the 'ALL-R-IGHT structure' workflow combining scaffold hopping, Fragment-Based Drug Discovery (FBDD), Differential Scanning Fluorimetry (DSF), and structure-based / computer-based design). On top of this unified discovery platform, the company maintains a portfolio of distinct pipeline candidates — CV-01, CV-02, CV-03, CV-P, and CV-T — each targeting a different disease (dementia/Alzheimer's, multiple sclerosis / autoimmune, cancer, metabolic/inflammatory disease, and Tau-related neurodegeneration respectively) at different development stages. The offering therefore consists of one discovery platform that produces multiple pipeline drug candidates, plus open business models (licensing, co-development, technology transfer) with global pharma partners, rather than a multi-module software suite.

Product and service2 records
1CV-01
CategorySmall molecule drug candidate — CNS / Neurodegeneration
Description

First-in-class oral small molecule Keap1/Nrf2 activator targeting brain inflammation. Selectively modifies Keap1 cysteine 151 via a reversible covalent bond to release Nrf2 and induce antioxidant/anti-inflammatory genes (HO-1, NQO1, GCLM, GCLC). Lead indication Alzheimer's disease, with expansion potential to Parkinson's, ALS, multiple sclerosis, chronic neuroinflammation and epilepsy. Designed with built-in BBB permeability, oral dosing, low hERG inhibition (IC50 = 112 μM) and favorable ADMET. For global pharma partners licensing the asset.

2CV-02
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CNS-focused biotech using structure-based small molecule design to develop differentiated therapies for neuropsychiatric and neurodegenerative diseases. Highly comparable to Cureverse's 'Right Structure' platform approach and CNS indication focus, though larger and now commercial (Caplyta).

TypeDirect peer
Description

CNS-focused biotech developing first-in-class small molecule therapies for neurological conditions. Comparable to Cureverse in CNS focus, small-molecule modality, and early-stage pipeline risk profile (Zurzuvae approved, multiple earlier-stage assets).

TypeDirect peer
Description

Biotech developing small molecule therapeutics for neurodegenerative diseases with emphasis on brain-penetrant, target-selective design. Highly comparable to Cureverse's BBB-permeability-first design philosophy and CNS pipeline.

TypeDirect peer
Description

CNS biotech developing differentiated small molecule therapies (xanomeline-trospium) for schizophrenia and other CNS indications. Comparable in CNS focus, small-molecule modality, and big-pharma partnership-driven commercialization model.

TypeBroad incumbent
Description

Private Italian pharmaceutical group and Cureverse's licensing partner for CV-01 global rights. Comparable as an established CNS-focused pharma that partners with/ acquires pipeline assets; provides a downstream commercialization reference for Cureverse's CV-01 economics.

TypeDirect peer
Description

CNS-focused biotech developing small molecule therapies for neuroscience disorders with structure-based design. Comparable in CNS pipeline focus and small-molecule modality; recently acquired by AbbVie, providing an exit-comparable for CNS-focused biotechs.

7Bristol Myers Squibb (S1P1 franchise)
TypeBroad incumbent
Description

Markets ozanimod (S1P1 modulator for MS/UC), directly relevant to Cureverse's CV-02 competitive landscape. Comparable as the established S1P1 commercial incumbent whose safety/efficacy bar CV-02 must clear.

TypeBroad incumbent
Description

Developed and markets fingolimod (Gilenya), the first-in-class S1P1 modulator for MS. Comparable as the originator of the S1P1 therapeutic class in which CV-02 competes.

TypeBroad incumbent
Description

Co-markets lecanemab (Leqembi) for early Alzheimer's with Biogen. Comparable as a major incumbent in the Alzheimer's treatment space where CV-01 competes, setting the efficacy/safety benchmark.

10H. Lundbeck
TypeBroad incumbent
Description

Specialty pharma focused on CNS disorders including neurodegenerative diseases. Comparable as a global CNS-focused commercial partner candidate for Cureverse's retained Korea/China rights.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cureverse

Biopharmaceutical Drug Discovery and Developmentcureverse.co.kr

Cureverse is a Seoul-based, KIST spin-off clinical-stage biotech (founded 2021, ~10 employees) developing orally bioavailable, brain-penetrant small molecule drugs for CNS diseases and oncology across five pipeline assets, monetized primarily through global out-licensing deals and government R&D grants ahead of a 2027 KOSDAQ IPO.

What Cureverse does

Cureverse (큐어버스) is a Seoul, South Korea-based clinical-stage biotech founded in October 2021 as a technology spin-off from the Korea Institute of Science and Technology (KIST), operating with approximately 10 employees. The company develops orally bioavailable, brain-penetrant small molecule drugs for intractable central nervous system diseases and oncology, organized around a proprietary 'Right Structure' / 'ALL-R-IGHT Structure' medicinal chemistry design philosophy. Its discovery platform integrates scaffold hopping, Fragment-Based Drug Discovery (FBDD), Differential Scanning Fluorimetry (DSF), and a proprietary in-house 'li-structure' (likelihood-to-be-a-drug) compound library customized per disease target to engineer drug-like properties (BBB permeability, ADMET, formulation ease) into candidates from the initial design stage.

The pipeline consists of five distinct small molecule candidates targeting different diseases and stages: CV-01, an oral selective Keap1/Nrf2 activator (first-in-class) for Alzheimer's and other neurodegenerative diseases, currently in Korean Phase 1 with a European bridge CTA planned for April 2026; CV-02, a biased S1P1 receptor agonist (best-in-class) for multiple sclerosis with US FDA Phase 1 IND approval received June 2025; CV-03, a selective DDR1 inhibitor for KRAS G12X-mutant lung and pancreatic cancers (preclinical, KDDF-selected); CV-P, a next-generation PPARδ agonist for metabolic/inflammatory diseases; and CV-T, a Tau aggregation inhibitor for Alzheimer's and related tauopathies.

Cureverse's business model is licensing- and partnership-driven rather than direct commercialization. The landmark October 2024 USD 370M technology transfer to Italy's Angelini Pharma for CV-01 global rights (ex-Korea/China) generated the bulk of 2025 recognized revenue (cumulative >KRW 10B / ~$7M), with the company pursuing a repeatable tech-transfer strategy targeting two additional preclinical/Phase 1 deals within five years. The company supplements licensing income with non-dilutive Korean government R&D grants (KDDF, DIPS, Global Cluster R&BD, KIST Biostar), Series B and planned pre-IPO venture funding (cumulative ~KRW 34B raised), and is targeting a 2027 KOSDAQ technology-special listing with Mirae Asset Securities as lead underwriter. Direct or partnered self-commercialization in Korea and China is planned post-Phase 3, with active partner search underway.

Cureverse firmographics

Firmographics
Name
Cureverse
Legal name
주식회사 큐어버스 (Jushikhoesa Cureverse)
Website
https://cureverse.co.kr
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Cureverse is a Seoul-based, KIST spin-off clinical-stage biotech (founded 2021, ~10 employees) developing orally bioavailable, brain-penetrant small molecule drugs for CNS diseases and oncology across five pipeline assets, monetized primarily through global out-licensing deals and government R&D grants ahead of a 2027 KOSDAQ IPO.
Ownership category
akta.pro rank

Cureverse industry classification

Industry
Product category
Biopharmaceutical Drug Discovery and Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Small molecule drug discovery
  • CNS therapeutics development
  • Oncology drug pipeline
  • Pharmaceutical licensing deals
  • Biotech pipeline assets

Where Cureverse is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Markets served

Cureverse business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Licensing & Royalty Income (CV-01): Out-licensing of CV-01 to Angelini Pharma for global rights ex-Korea/China, structured as an upfront payment plus development/regulatory/sales milestone payments (total contract value USD 370M / ~KRW 500–537B) plus ongoing sales royalties. Korea and China commercial rights retained by Cureverse for self-development.
  2. Tech Transfer / Out-licensing Pipeline: Strategy of repeatedly executing early-stage (preclinical or Phase 1) tech transfer deals for each pipeline asset to generate milestone-based cash flow that funds further internal pipeline development. CEO targets two additional tech transfer deals within five years.
  3. Government R&D Grants (National/Regional Programs): Non-dilutive R&D funding from Korean government programs including KDDF (Korea Drug Development Fund), Korea National R&D Program for Dementia, DIPS (Deep Tech TIPS 1000+), Korea SMEs & Startups Agency (아기 유니콘), Seoul R&D, KIST biostar, and Global Cluster R&BD. Funds preclinical, IND, and clinical bridging studies.
  4. Venture Capital Investment (Series B and Pre-IPO): Venture capital funding, including a KRW 25B Series B closed in early 2025 (cumulative KRW 34B raised), with a planned pre-IPO round in H2 of the IPO year to support Phase 2/3 development and commercialization infrastructure.
  5. Future Direct Self-Commercialization (Korea/China rights): Planned direct sale of CV-01 (and potentially other assets) in Korea and China markets where Cureverse retains commercial rights, with active partner search for a single licensee for both territories. Currently searching for a Korean partner with a China network.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractBespoke licensing deal pricing (CV-01 to Angelini Pharma)

Go-to-market motion3 records

Cureverse product offering

Product offering

Core offering

Cureverse is a preclinical-to-clinical-stage Korean biotechnology company that discovers and develops first-in-class and best-in-class small molecule drug candidates for intractable CNS, oncology and inflammatory/fibrotic diseases using a proprietary structure-based medicinal chemistry platform ('Right Structure' / 'ALL-R-IGHT structure'). Its current commercial offerings are pipeline drug assets — CV-01 (oral Keap1/Nrf2 activator), CV-02 (biased S1P1 agonist), CV-03 (DDR1 inhibitor), CV-P (next-generation PPARδ agonist) and CV-T (Tau aggregation inhibitor) — which it monetizes primarily through B2B out-licensing, co-development and technology transfer deals with global pharmaceutical partners (anchor transaction: USD 370M CV-01 deal with Angelini Pharma in October 2024).

Product overview

Cureverse is a single-platform Korean biotech company built around a proprietary small-molecule drug discovery engine called 'Right Structure' (operationalized as the 'ALL-R-IGHT structure' workflow combining scaffold hopping, Fragment-Based Drug Discovery (FBDD), Differential Scanning Fluorimetry (DSF), and structure-based / computer-based design). On top of this unified discovery platform, the company maintains a portfolio of distinct pipeline candidates — CV-01, CV-02, CV-03, CV-P, and CV-T — each targeting a different disease (dementia/Alzheimer's, multiple sclerosis / autoimmune, cancer, metabolic/inflammatory disease, and Tau-related neurodegeneration respectively) at different development stages. The offering therefore consists of one discovery platform that produces multiple pipeline drug candidates, plus open business models (licensing, co-development, technology transfer) with global pharma partners, rather than a multi-module software suite.

Differentiator

Problem solved

Functional benefit

Products and services

  • CV-01 First-in-class oral small molecule Keap1/Nrf2 activator targeting brain inflammation. Selectively modifies Keap1 cysteine 151 via a reversible covalent bond to release Nrf2 and induce antioxidant/anti-inflammatory genes (HO-1, NQO1, GCLM, GCLC). Lead indication Alzheimer's disease, with expansion potential to Parkinson's, ALS, multiple sclerosis, chronic neuroinflammation and epilepsy. Designed with built-in BBB permeability, oral dosing, low hERG inhibition (IC50 = 112 μM) and favorable ADMET. For global pharma partners licensing the asset.
  • CV-02

Companies that use Cureverse

Customer profile

Segments1 record

Ideal customer profiles3 records

Cureverse technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Cureverse partnerships and signals

Strategic signal

Recent moves9 records

Expansion highlights7 records

Cureverse competitors and assessment

Company assessment

Direct peers

  • Intra-Cellular Therapies: Clinical-stage CNS-focused biotech using structure-based small molecule design to develop differentiated therapies for neuropsychiatric and neurodegenerative diseases. Highly comparable to Cureverse's 'Right Structure' platform approach and CNS indication focus, though larger and now commercial (Caplyta).
  • Sage Therapeutics: CNS-focused biotech developing first-in-class small molecule therapies for neurological conditions. Comparable to Cureverse in CNS focus, small-molecule modality, and early-stage pipeline risk profile (Zurzuvae approved, multiple earlier-stage assets).
  • Denali Therapeutics: Biotech developing small molecule therapeutics for neurodegenerative diseases with emphasis on brain-penetrant, target-selective design. Highly comparable to Cureverse's BBB-permeability-first design philosophy and CNS pipeline.
  • Karuna Therapeutics: CNS biotech developing differentiated small molecule therapies (xanomeline-trospium) for schizophrenia and other CNS indications. Comparable in CNS focus, small-molecule modality, and big-pharma partnership-driven commercialization model.
  • Cerevel Therapeutics: CNS-focused biotech developing small molecule therapies for neuroscience disorders with structure-based design. Comparable in CNS pipeline focus and small-molecule modality; recently acquired by AbbVie, providing an exit-comparable for CNS-focused biotechs.

Broad incumbents

  • Angelini Pharma: Private Italian pharmaceutical group and Cureverse's licensing partner for CV-01 global rights. Comparable as an established CNS-focused pharma that partners with/ acquires pipeline assets; provides a downstream commercialization reference for Cureverse's CV-01 economics.
  • Bristol Myers Squibb (S1P1 franchise): Markets ozanimod (S1P1 modulator for MS/UC), directly relevant to Cureverse's CV-02 competitive landscape. Comparable as the established S1P1 commercial incumbent whose safety/efficacy bar CV-02 must clear.
  • Novartis (S1P1 franchise): Developed and markets fingolimod (Gilenya), the first-in-class S1P1 modulator for MS. Comparable as the originator of the S1P1 therapeutic class in which CV-02 competes.
  • Eisai (Alzheimer's franchise): Co-markets lecanemab (Leqembi) for early Alzheimer's with Biogen. Comparable as a major incumbent in the Alzheimer's treatment space where CV-01 competes, setting the efficacy/safety benchmark.
  • H. Lundbeck: Specialty pharma focused on CNS disorders including neurodegenerative diseases. Comparable as a global CNS-focused commercial partner candidate for Cureverse's retained Korea/China rights.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Cureverse social profiles

Digital presence

Cureverse compliance and trust

Trust signal

Compliance3 records

Cureverse financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cureverse leadership team

Management profile

Number of profiles

Profiles5 records

Cureverse funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cureverse M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cureverse

What does Cureverse do?

Cureverse is a preclinical-to-clinical-stage Korean biotechnology company that discovers and develops first-in-class and best-in-class small molecule drug candidates for intractable CNS, oncology and inflammatory/fibrotic diseases using a proprietary structure-based medicinal chemistry platform ('Right Structure' / 'ALL-R-IGHT structure'). Its current commercial offerings are pipeline drug assets — CV-01 (oral Keap1/Nrf2 activator), CV-02 (biased S1P1 agonist), CV-03 (DDR1 inhibitor), CV-P (next-generation PPARδ agonist) and CV-T (Tau aggregation inhibitor) — which it monetizes primarily through B2B out-licensing, co-development and technology transfer deals with global pharmaceutical partners (anchor transaction: USD 370M CV-01 deal with Angelini Pharma in October 2024).

Is Cureverse a public or private company?

Cureverse is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cureverse founded?

Cureverse was founded in 2021. It employs 11 to 50 people.

Where is Cureverse based?

Cureverse is headquartered in Seoul, South Korea, in the Asia region.

How does Cureverse make money?

Five revenue lines are on record. Licensing & Royalty Income (CV-01) is the primary driver. The others are tech Transfer / Out-licensing Pipeline, government R&D Grants (National/Regional Programs), venture Capital Investment (Series B and Pre-IPO) and future Direct Self-Commercialization (Korea/China rights).

Who are Cureverse's main competitors?

Direct peers on record are Intra-Cellular Therapies, Sage Therapeutics, Denali Therapeutics, Karuna Therapeutics and Cerevel Therapeutics. Broad incumbents are Angelini Pharma, Bristol Myers Squibb (S1P1 franchise), Novartis (S1P1 franchise), Eisai (Alzheimer's franchise) and H. Lundbeck.

Does Cureverse have an API?

No public API is recorded for Cureverse.

What industry is Cureverse in?

Cureverse's product category is Biopharmaceutical Drug Discovery and Development. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
스타트업엔(StartupN)Cureverse selected as 'Top-tier overseas talent attraction (bio)'... receiving 1.5 billion won to strengthen global clinical capabilities.Cureverse was selected for the 2026 'Top-tier Foreign Talent Recruitment (Bio)' project, receiving 1.5 billion won over two years and six months. The company plans to internalize global clinical development experience and advance its CV-01 and CV-02 pipelines, with CV-01 in final domestic Phase 1 trials.스타트업엔(StartupN)Curebus, selected for government project on dementia treatment... Secured 3.1 billion won and accelerated entry into Phase 2 clinical trials.Cureverse was selected for a government dementia treatment project, securing 3.1 billion won in funding. The company will accelerate its Alzheimer's candidate CV-01, moving from Phase 1 to Phase 2a trials. The project aims to shorten development time through parallel clinical and non-clinical trials.BiospectatorCureverse, 'NRF2 Activator' selected as a phase 1 government project for overcoming dementiaCureverse was selected for a government dementia project with 3.1 billion won support to complete Phase 1 and start Phase 2a of its CV-01 Alzheimer's treatment. The company plans to finish Phase 1 and submit Phase 2a IND after 26-39 week GLP toxicity tests.ChosunbizKorea honors Cureverse, Alteogen, Inventage Lab for health industry achievementsKorea's health ministry and KHIDI held a 2025 performance exchange meeting, awarding 78 orders, medals, and commendations across four fields. Cureverse CEO received the Magnolia Medal for a $360 million technology transfer to Italy's Angelini Pharma, and Alteogen and Inventage Lab were commended for their R&D contributions.ChosunbizCureVerse achieves 500 billion won in tech exports through innovative dementia drugCureVerse, a KIST spinoff, signed a $370 million technology export deal with Angelini Pharma for its dementia drug CV-01, the largest export by a government-funded institute. The company has raised 34 billion won and achieved over 500 billion won in exports in three years. CV-01's Phase 1 trials are expected to complete this year, with Phase 2 trials planned.NatureThe KDDF immunology pipeline: translating cutting-edge science into novel therapeuticsKorea Drug Development Fund supports immunology R&D, with 44 of 391 projects since 2021. Three companies are highlighted: AmtixBio's ATB1606 for atopic dermatitis, CUREVERSE's CV-01 for Alzheimer's, and Innovo's INV-101 for ulcerative colitis. Phase 1 trials are planned or ongoing for these candidates.GlobeNewswireAngelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health AssetAngelini Pharma has entered into an exclusive global option agreement with Cureverse to develop and commercialize CV-01, a novel Phase 1 investigational compound targeting brain health disorders such as epilepsy and Alzheimer’s disease. Under the deal, Angelini will lead development efforts outside of specific Asian markets where Cureverse retains rights, while receiving potential milestone payments totaling approximately US$360 million plus royalties. The collaboration aims to leverage Angelini’s therapeutic expertise and Cureverse’s early development capabilities to address significant unmet needs in neurological conditions.News1Cureverse, Alzheimer's drug candidate 'CV-01' Phase 1 plan approvedCureverse received approval from the Ministry of Food and Drug Safety to conduct a Phase 1 clinical trial for its oral Alzheimer's drug candidate, CV-01. The study will involve 110 healthy participants across two age groups at Seoul National University Hospital until December 2025 to evaluate safety and pharmacokinetics. This development marks an acceleration in Cureverse's efforts to treat degenerative diseases through a novel mechanism targeting Keap1·Nrf2 protein interactions.